Literature DB >> 2111204

Valproic acid and panic disorder.

F Primeau1, R Fontaine, L Beauclair.   

Abstract

Valproic acid (VA), an anticonvulsant which increases GABAergic transmission was given to patients suffering from recurrent panic attacks. Ten consecutive outpatients were included in this study. After a seven day placebo washout period, patients were given a dose of 500 mg/day, which was gradually increased to a maximum of 2250 mg/day. A significant improvement was found in the symptomatology of patients as measured on the Clinical Global Impression Scale for panic severity (p less than 0.001), the Hamilton Psychiatric Rating Scale for Anxiety (p less than 0.001) and the panic factor of the SCL-90 (p less than 0.05). These findings support the hypothesis that VA is useful in the treatment of panic disorders. Further research should be carried out to assess its efficacy and safety.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2111204     DOI: 10.1177/070674379003500309

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  16 in total

1.  Pharmacological, toxicological and neurochemical effects of delta 2(E)-valproate in animals.

Authors:  P E Keane
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 2.  Anticonvulsants in anxiety disorders.

Authors:  Gustavo Kinrys; Lisa E Wygant
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

3.  Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants: a 3-year "open" follow-up study.

Authors:  Giulio Perugi; Franco Frare; Cristina Toni; Giuseppe Tusini; Giulia Vannucchi; Hagop S Akiskal
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-03-18       Impact factor: 5.270

4.  Sodium valproate and clonazepam for treatment-resistant panic disorder.

Authors:  A Ontiveros; R Fontaine
Journal:  J Psychiatry Neurosci       Date:  1992-06       Impact factor: 6.186

Review 5.  Antiepileptic drugs in the treatment of anxiety disorders: role in therapy.

Authors:  Michael Van Ameringen; Catherine Mancini; Beth Pipe; Mark Bennett
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  [Anticonvulsants in the treatment of anxiety--an alternative treatment option?].

Authors:  P Zwanzger; D Eser; R Rupprecht
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214

Review 7.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

Review 8.  Epidemiology and management of anxiety in patients with bipolar disorder.

Authors:  Marcia Kauer-Sant'Anna; Flavio Kapczinski; Eduard Vieta
Journal:  CNS Drugs       Date:  2009-11       Impact factor: 5.749

9.  A risk-benefit assessment of pharmacological treatments for panic disorder.

Authors:  J A Bennett; M Moioffer; S P Stanton; M Dwight; P E Keck
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

10.  The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic.

Authors:  Jeffrey R Strawn; Thomas D Geracioti
Journal:  Neuropsychiatr Dis Treat       Date:  2007-04       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.